8-K: DMAA Appoints New CFO, Grants 100K Shares

Drugs Made In America Acquisition Corp. announced the resignation of its CFO, Glenn Worman, and the appointment of Saleem Elmasri, a seasoned financial professional, effective November 17, 2025.

Summary

• Glenn Worman resigned from his position as Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition Corp., effective October 8, 2025.
• Mr. Worman indicated that his resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
• Saleem Elmasri was appointed as the new Chief Financial Officer and principal financial and accounting officer, with his appointment effective beginning November 17, 2025.
• The Company entered into a Master Services Agreement with Titan Advisory Services LLC, Mr. Elmasri's firm, for his services, agreeing to pay $42,000 per year, or $3,500 per month.
• Additionally, Mr. Elmasri will receive a grant or transfer of 100,000 ordinary shares of the Company upon engagement.
• Mr. Elmasri is a CPA with 20 years of experience in financial and management consulting, including prior roles at PricewaterhouseCoopers, DLA LLC, and Pine Hill Group LLC, with a focus on the Life Sciences and Pharmaceutical industry.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a CFO resignation is typically a concern, the explicit statement that it was not due to disagreement, coupled with the appointment of a highly qualified replacement, mitigates negative sentiment. The equity grant to the new CFO also aligns interests.

Positives

• The appointment of Saleem Elmasri, a highly experienced CPA with 20 years in financial and management consulting, including significant experience in the Life Sciences and Pharmaceutical industry, strengthens the Company's financial leadership.
• Mr. Worman's resignation was explicitly stated not to be a result of any disagreement with the Company's operations, policies, or practices, which mitigates potential concerns regarding management stability.
• The equity grant of 100,000 ordinary shares to the new CFO aligns his interests with those of the Company's shareholders.

Negatives

• The departure of a principal financial officer, even if amicable, can introduce a period of transition and potential disruption to financial operations and reporting.

Future Outlook

The filing primarily details past and immediate future personnel changes and does not provide broader forward-looking statements or guidance on the Company's performance or strategic direction. It notes that Mr. Elmasri is expected to enter into standard officer agreements.

Management Comments

• Mr. Worman indicated that his resignation was not the result of any disagreement with the Company regarding its operations, policies, practices or otherwise.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) undergoing management changes. The appointment of a CFO with extensive experience in the Life Sciences and Pharmaceutical industries aligns with the Company's name, 'Drugs Made In America Acquisition Corp.', suggesting a continued focus on that sector for potential business combinations.

Comparison to Industry Standards

• The compensation structure, which includes a base fee and a significant equity grant (100,000 shares), is a common practice for attracting experienced executives to early-stage or SPAC entities, where cash compensation might be lower but equity upside is substantial.
• The appointment of a CPA with Big-4 accounting experience (PricewaterhouseCoopers) and specialized advisory roles is standard for a public company's principal financial officer, ensuring robust financial reporting and compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO and the equity grant could be seen positively, ensuring financial oversight and aligning management incentives. The amicable departure of the previous CFO reduces uncertainty.
• Employees: No direct impact mentioned, but a stable leadership team generally benefits employee morale.
• Customers/Suppliers: No direct impact mentioned.
• Creditors: A strong financial officer can enhance confidence in the company's financial management.

Next Steps

• Saleem Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement, and a Registration Rights Agreement with the Company on the same terms as other directors and officers.

Key Dates

Recommendation

The filing details a standard management transition with the resignation of the CFO and the appointment of a highly qualified replacement. The explicit statement that the resignation was not due to disagreements mitigates potential negative concerns. While the new CFO's experience is a positive, this type of announcement typically does not provide new fundamental information to warrant a change in investment thesis for a SPAC, which is primarily driven by its eventual business combination. Therefore, a 'hold' recommendation is appropriate as investors await further strategic developments.

Keywords

Drugs Made In America Acquisition Corp, DMAA, CFO appointment, Chief Financial Officer, Saleem Elmasri, Glenn Worman, SPAC, financial officer change, corporate governance, executive change, Titan Advisory Services